SCHEMBL181879

SCHEMBL181879

CCOC(=O)C(=O)C1CCCCC1=O

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.48
MAPK1 P28482 1/20 0.44
MCL1 Q07820 1/20 0.42
TLR4 O00206 1/20 0.40
KMT2A Q03164 3/20 0.39
ALDH1A1 P00352 4/20 0.37
MAPT P10636 2/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA4 P22748 1/20 0.37
GAA P10253 3/20 0.37
THRB P10828 1/20 0.36
ATM Q13315 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM4E B2RXH2 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1149626 0.98 CYP2D6 (0.47) CYP2D6MAPK1MCL1TLR4KMT2A
SCHEMBL10080626 0.98 CYP2D6 (0.47) CYP2D6MAPK1MCL1TLR4KMT2A
SCHEMBL5109918 0.95 CYP2D6 (0.42) CYP2D6MAPK1MCL1TLR4KMT2A
SCHEMBL276016 0.83 TLR4 (0.51) CYP2D6MAPK1MCL1TLR4KMT2A
SCHEMBL2470785 0.83 TLR4 (0.51) CYP2D6MAPK1MCL1TLR4KMT2A
SCHEMBL13745224 0.81 CYP2D6 (0.38) CYP2D6MAPK1TLR4KMT2AALDH1A1
SCHEMBL28368812 0.81 TLR4 (0.50) CYP2D6MAPK1MCL1TLR4KMT2A
SCHEMBL7392059 0.81 TLR4 (0.50) CYP2D6MAPK1MCL1TLR4KMT2A
SCHEMBL7733726 0.81 TLR4 (0.50) CYP2D6MAPK1MCL1TLR4KMT2A
SCHEMBL10792572 0.81 TLR4 (0.50) CYP2D6MAPK1MCL1TLR4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-60008252-A None JP disclosed
US-20250282785-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2025-09-11 US disclosed
EP-4522608-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN Pharmaceutica NV (BE) 2025-03-19 EP disclosed
CN-117916231-A Compounds for inhibiting or degrading target proteins, compositions comprising the same, methods of making and methods of using the same 纽力克斯治疗公司 2024-04-19 CN disclosed
EP-4334302-A1 COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE Nurix Therapeutics, Inc. (US) 2024-03-13 EP disclosed
WO-2023217906-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2023-11-16 WO disclosed
US-20230158151-A1 COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE NURIX THERAPEUTICS, INC. 2023-05-25 US disclosed
US-20230097420-A1 INDAZOLE HYDRAZIDE COMPOUND AND APPLICATION THEREOF PEKING UNIVERSITY FIRST HOSPITAL (CN) 2023-03-30 US disclosed
CN-108484600-B URAT1 inhibitors for promoting uric acid excretion 江苏新元素医药科技有限公司 2022-12-13 CN disclosed
WO-2022235698-A1 COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE NURIX THERAPEUTICS, INC. (US) 2022-11-10 WO disclosed
EP-1735286-A1 TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-27 EP disclosed
US-20060014756-A1 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2006-01-19 US disclosed
US-20050228034-A1 Tetrahydro-indazole cannabinoid modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2005-10-13 US disclosed
WO-2005095353-A1 TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-10-13 WO disclosed
US-6897208-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2005-05-24 US disclosed
EP-1441725-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS Aventis Pharmaceuticals Inc. (US) 2004-08-04 EP disclosed
US-20040048868-A1 Benzimidazoles AVENTISUB LLC 2004-03-11 US disclosed
WO-2003035065-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2003-05-01 WO disclosed
JP-S608252-A SALICYLIC ACID DERIVATIVE AND HERBICIDE SHOWA DENKO KK 1985-01-17 JP disclosed
US-4256639-A Process for the synthesis of isatin derivatives AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO (IT) 1981-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014756-A1 Benzimidazoles CDK9, BMX, SBK3 CYP2D6 212/4885MAPK1 154/4885MCL1 1314/4885
US-20040048868-A1 Benzimidazoles CDK9, BMX, CDKN1A CYP2D6 235/4885MAPK1 23/4885MCL1 743/4885
US-20250282785-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE NFKBIA, IKBKG, IKBKB CYP2D6 4633/4885MAPK1 280/4885MCL1 636/4885
US-20050228034-A1 Tetrahydro-indazole cannabinoid modulators CNR2, CNR1, GPR18 CYP2D6 758/4885MAPK1 2032/4885MCL1 1606/4885
US-20230158151-A1 COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE MDM2, XIAP, ADRM1 CYP2D6 3652/4885MAPK1 3491/4885MCL1 209/4885
US-20230097420-A1 INDAZOLE HYDRAZIDE COMPOUND AND APPLICATION THEREOF ITGB3, AR, HDAC3 CYP2D6 1297/4885MAPK1 2900/4885MCL1 2011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.